Patent EP3515945A1: Anti-STEAP2 Antibodies, Drug Conjugates, Uses

The European Patent Office has published patent application EP3515945A1 concerning anti-STEAP2 antibodies, antibody-drug conjugates, and their uses, filed by Regeneron Pharmaceuticals, Inc. The patent application details specific molecular entities and their therapeutic applications, particularly in oncology.

EPO Patent Publication: BAFF-R Targeted CAR T-cells

The European Patent Office published patent application EP3464371A1 on March 11, 2026, concerning BAFF-R targeted chimeric antigen receptor-modified T-cells and their uses. The patent application lists City of Hope and The University of Texas System as applicants.

EPO Patent Bulletin: Immune Stimulating Antibodies Against IL-2 Fusion Proteins

The European Patent Office has published patent application EP3402819A1 concerning immune-stimulating humanized monoclonal antibodies against human interleukin-2 and fusion proteins thereof. The patent application was published on March 11, 2026, by applicant Universität Zürich.

EPO Patent EP3356393A1: Chimeric Proteins for Extracellular Domains

The European Patent Office has published patent application EP3356393A1 concerning chimeric proteins for adjoining extracellular domains. The patent, filed by Kopfkino IP, LLC, details compositions and methods related to these protein structures.

EPO Patent Bulletin: Antigen-binding proteins targeting CD56

The European Patent Office has published patent application EP3328994A1 concerning antigen-binding proteins targeting CD56 and their uses. The patent was filed by Memorial Sloan-Kettering Cancer Center and the U.S. Department of Health and Human Services.

EPO Patent Publication EP3390433A1: Novel Cytokine Fusion Proteins

The European Patent Office has published patent application EP3390433A1 for BioNTech SE, detailing novel cytokine fusion proteins. This publication is part of the EPO Bulletin and relates to advancements in peptide technology.

EPO Patent Bulletin - Antibody Molecules Binding CD45

The European Patent Office (EPO) has published patent application EP3322729A1 concerning antibody molecules that bind CD45. The publication details the applicant, UCB Biopharma SRL, and the inventors, along with International Patent Classification codes related to peptides, antibodies, and therapeutic uses.

Patent EP2919859A1: Collagen with Metallic Anticancer Agents

The European Patent Office has published patent application EP2919859A1, filed by MIMEDX Group Inc. The patent describes cross-linked collagen comprising metallic anticancer agents. The publication date is March 11, 2026.

CLC Intent to Use Trademark Application

The USPTO has received an Intent to Use trademark application (TM98259610) from CLC for digital media and entertainment production services. The application was filed on November 7, 2023.

USPTO Trademark Application - K&K Eyeglasses/Sunglasses

The USPTO has received an intent-to-use trademark application (TM98222917) from K&K for "Eyeglasses; Sunglasses" in Class 009. The application was filed on October 13, 2023, and is marked for an intent-to-use status with a target date of March 24, 2026.